ANI Pharmaceuticals (NASDAQ:ANIP) SVP Chad Gassert Sells 14,642 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert sold 14,642 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the transaction, the senior vice president owned 158,584 shares in the company, valued at approximately $14,125,076.88. This represents a 8.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Chad Gassert also recently made the following trade(s):

• On Thursday, November 13th, Chad Gassert sold 94 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $88.00, for a total value of $8,272.00.

ANI Pharmaceuticals Stock Down 0.6%

NASDAQ:ANIP traded down $0.53 during trading hours on Friday, hitting $84.02. The stock had a trading volume of 394,304 shares, compared to its average volume of 370,722. The company has a market cap of $1.82 billion, a PE ratio of -109.12 and a beta of 0.54. The business has a 50 day simple moving average of $92.77 and a two-hundred day simple moving average of $78.13. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business’s revenue was up 53.6% on a year-over-year basis. During the same period last year, the business earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ANIP. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Monday. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, HC Wainwright upped their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $99.29.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Global Alpha Capital Management Ltd. boosted its stake in ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after acquiring an additional 126,500 shares during the period. UBS Group AG boosted its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the period. Aberdeen Group plc grew its stake in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after buying an additional 181,134 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in ANI Pharmaceuticals during the 3rd quarter worth $32,992,000. Finally, Rubric Capital Management LP increased its position in ANI Pharmaceuticals by 33.3% in the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after buying an additional 85,745 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.